| I-10 John C Lukas Order in patch absorption rates? Wednesday 10:30-12:00 |
| I-18 Dimitris Maris Asymptotic Analysis on a TMDD model: Control of the process Wednesday 10:30-12:00 |
| I-21 Nicola Melillo Multiscale mechanistic models in Systems Pharmacology: development of a model describing Atorvastatin pharmacokinetics through integration of metabolic network in Physiologically Based Pharmacokinetic models. Wednesday 10:30-12:00 |
| I-25 Daniel Moj Application of a physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat to improve dosing regimens in adults Wednesday 10:30-12:00 |
| I-59 Christer Rimmler Development of a PBPK model to predict the pharmacokinetics of cefuroxime during surgery Wednesday 10:30-12:00 |
| I-61 Amin Rostami Predicting diclofenac systemic and synovial fluid concentrations after dermal application using the Multi-Phase Multi-Layer MechDermA PBPK model Wednesday 10:30-12:00 |
| II-11 Mahendra Shukla Population Pharmacokinetic-Pharmacodynamic modeling of furosemide for anti-hypertensive effect Wednesday 15:10-16:30 |
| II-15 Konstantina Soulele Population pharmacokinetic analysis of inhaled budesonide in asthma patients Wednesday 15:10-16:30 |
| II-26 Donato Teutonico Development of a PBPK model to describe late colonic absorption after oral administration Wednesday 15:10-16:30 |
| II-32 Periklis Tsiros Bayesian Whole Body Population Physiologically Based Pharmacokinetic Approach for Characterization of Interindividual Variability of Diazepam Wednesday 15:10-16:30 |
| II-34 Denise Feick Physiologically-Based Pharmacokinetic (PBPK) Modeling of the CYP2C8 Substrate Pioglitazone Wednesday 15:10-16:30 |
| II-58 Jan-Georg Wojtyniak Physiologically-based Pharmacokinetic (PBPK) Modeling of Simvastatin Drug-Drug Interactions with Rifampin, Clarithromycin and Drug-Gene Interaction with ABCG2 Wednesday 15:10-16:30 |
| II-67 Zakaria Zaril A Mechanistic Pharmacokinetic Approach to the Development of Predictive Models in HIV-malaria co-infection. Wednesday 15:10-16:30 |
| III-01 Elin Boger Drug targeting in pulmonary sub-epithelial compartments predicted through systems pharmacology modelling Thursday 09:50-11:20 |
| III-03 Elvira Erhardt Comparison of pharmacokinetic parameters estimated by the experimental R package 'nlmixr' and MONOLIX Thursday 09:50-11:20 |
| III-11 Iain Gardner A Whole body Physiologically based Pharmacokinetic Model for Antibody drug conjugates - model development and validation in rat Thursday 09:50-11:20 |
| III-21 Silvia Grandoni Evaluation of a minimal WB-PBPK platform supporting different routes of administration Thursday 09:50-11:20 |
| III-23 Benjamin Guiastrennec Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in human Thursday 09:50-11:20 |
| III-28 Nina Hanke Physiologically-based pharmacokinetic (PBPK) modeling of alfentanil as a CYP3A4 victim drug Thursday 09:50-11:20 |
| III-32 Eleanor Howgate Sensitivity analysis of P-glycoprotein Ki values in dynamic DDI predictions Thursday 09:50-11:20 |
| III-35 Ibrahim Ince Extension of a pregnancy physiologically-based pharmacokinetic model for renally cleared drugs to the postpartum period Thursday 09:50-11:20 |
| III-37 Masoud Jamei Virtual Bioequivalence Assessment of Two Tramadol Formulations using the Advanced Dissolution Absorption and Metabolism (ADAM) model via Simcyp R Package Thursday 09:50-11:20 |
| III-40 Jihyun Jeon Pharmacokinetic modeling of Donepezil after transdermal administration in rat Thursday 09:50-11:20 |
| III-46 Vangelis Karalis On the population pharmacokinetics and the enterohepatic recirculation of inhaled formoterol in asthma patients Thursday 09:50-11:20 |
| III-65 Jong Bong Lee In silico modelling of chylomicron association to predict lymphatic absorption of small molecules Thursday 09:50-11:20 |
| IV-01 Khaled Abduljalil Application of Physiologically-Based Pharmacokinetic model To Predict Tramadol Concentration in human Milk Thursday 14:45-16:15 |
| IV-10 Hyun-moon Back Development of a Semi-mechanistic absorption model for explaining effect of food on itraconazole Thursday 14:45-16:15 |
| IV-12 Pavel Balazki Physiologically-based Pharmacokinetics/Pharmacodynamics model of Dapagliflozin, an oral SGLT2 inhibitor Thursday 14:45-16:15 |
| IV-27 Jantine Brussee Distinguishing between first-pass and systemic CYP3A-mediated metabolism of midazolam in preterm neonates using physiologically-based pharmacokinetic modelling Thursday 14:45-16:15 |
| IV-33 Letizia Carrara Which data are necessary to build a WB-PBPK model that accurately predicts exposure in the lung? A case study using Ethambutol for tuberculosis treatment Thursday 14:45-16:15 |
| IV-41 Manoranjenni Chetty Prediction of the pharmacokinetics of renally excreted antiretrovirals in older patients, using physiologically based pharmacokinetic (PBPK) modelling. Thursday 14:45-16:15 |
| IV-51 André Dallmann Physiologically-based pharmacokinetic modeling of drugs metabolized via several CYP enzymes in populations of pregnant women Thursday 14:45-16:15 |
| IV-54 Mailys De Sousa Mendes Predicting human foetal exposure using physiologically based pharmacokinetic models Thursday 14:45-16:15 |
